🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Cologne
Clinical trial register · Germany

Clinical Trials in Cologne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Novartis Pharmaceuticals29 University of Cologne25 Janssen Research & Development, LLC21 Bristol-Myers Squibb21
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Cologne

612 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Berlin, Hanover, Münster, Cologne, Homburg, Leipzig, Kiel, Essen
2027-11-23
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg
2027-02-03
Not yet open
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
NCT07084831Schizophrenia; Psychosis, Cognitive Impairment
European Group for Research In Schizophrenia
Phase 3
171
Augsburg, Cologne, Mannheim, München
2027-01-01
Not yet open
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
NCT07699640Testicular Cancer, Testicular Germ Cell Tumor
Heinrich-Heine University, Duesseldorf
Not applicable
171
Ulm, Würzburg, Hamburg, Marburg, Cologne, Düsseldorf, Wuppertal, Dresden
2027-01
Not yet open
Dalbavancin Therapy for Infective Endocarditis
NCT07699211Endocarditis Infective, Endocarditis, Bacterial
DrugDalbavancin administration
Stefan Hagel
Phase 3
184
Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena
2026-12
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne
2026-11-30
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
DrugNerandomilast
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-11-09
Not yet open
Intraoperative Application of Cold Atmospheric Plasma to Prevent Postoperative Wound Complications in the Inguinal Region of High-risk Patients With Peripheral Arterial Occlusive Disease
NCT07571408Peripheral Occlusive Disease, Wound Healing, Wound Healing Complication, Cold Atmospheric Plasma
Ursula Werra
Not applicable
214
Cologne
2026-11-01
Not yet open
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
NCT07840456Carcinoma, Squamous Cell of Head and Neck HNSCC
DrugsRuxolitinib·Pembrolizumab
University Hospital, Basel, Switzerland
Phase 2
66
Würzburg, Greifswald, Cologne, Hagen, Hamburg
2026-11
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
Gerlingen, Ulm, Wangen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne
2026-09-30
Not yet open
External Beam Radiotherapy Combined With Endorectal High-dose-rate Brachytherapy in Elderly and Frail Patients With Rectal Cancer
NCT06729645Rectal Cancer
University Hospital of Cologne
Not applicable
80
Kempten, Frankfurt am Main, Cologne, Leipzig
2026-09-30
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
München, Berlin, Cologne, Herne, Sendenhorst
2026-09-15
Not yet open
Catheter Ablation for AF in Patients With Severe Mitral Regurgitation After Successful Transcatheter Mitral-Valve Repair
NCT07380932Atrial Fibrillation (AF), Mitral Valve (MV) Regurgitation
Atrial Fibrillation Network
Not applicable
956
Cologne, Frankfurt, Hamburg, Münster
2026-09-01
Not yet open
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
NCT07721649Acute Coronary Syndrome, Heart Failure, Influenza, Human, Cardiovascular Diseases
Stephan Baldus
Not applicable
482
Cologne, Hamburg
2026-09
Not yet open
Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN Trial
NCT07788586Candidemia, Invasive Candidiasis
Oliver Cornely, MD
Phase 4
420
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen
2026-09
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
University of Oxford
Phase 3
250
Augsburg, Berlin, Cologne, Munich
2026-09
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsImzokitug·Vedolizumab·Infliximab·Pumitamig
Bristol-Myers Squibb
Phase 2
160
Stuttgart, Marburg, Homburg, Cologne, Haile, Hessen
2026-08-31
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study
NCT07621003Atrial Fibrillation
Asklepios proresearch
Not applicable
264
Bad Oeynhausen, Cologne, Düsseldorf, Frankfurt, Giessen, Hamburg, Herne, Leipzig
2026-08-19
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Cologne
2026-08-17
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Aachen, Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Hanover
2026-08-05
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Carboplatin
SystImmune Inc.
Phase 3
550
Cologne, Essen, Halle
2026-08-04
Not yet open
Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients
NCT06414122Oesophageal Cancer, Gastric Cancer, Duodenal Cancer, Colorectal Cancer
University of Cologne
Not applicable
88
Cologne
2026-08-01
Recruiting
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
NCT07549698Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
DrugCTX112
CRISPR Therapeutics AG
Phase 1/2
60
Cologne, Hannover, Hanover, Mainz
2026-07-17
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
DrugsObrixtamig·Etoposide·Carboplatin
Boehringer Ingelheim
Phase 3
390
Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg
2026-07-10
Recruiting
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT07672236Head & Neck Cancer, Oral Mucositis
OncoZenge AB
Phase 3
150
Cologne, Frankfurt am Main, Freiburg im Breisgau, Kiel, Tübingen
2026-07-07
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109Type 2 Diabetes Mellitus
DrugsElecoglipron·Dapagliflozin
AstraZeneca
Phase 3
2,000
Berlin, Cologne, Damme, Deggingen, Duisburg, Essen, Falkensee, Frankfurt
2026-07-06
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241Small Cell Lung Cancer
DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan
AbbVie
Phase 3
531
Würzburg, Kassel, Cologne
2026-07-02
Active, closed
Artificial Intelligence(AI) in the Emergency Department (ED) in Cologne
NCT07725965Emergency Care, Clinical Decision Support, Triage
University of Cologne
Observational
100,000
Cologne
2026-07-01
Not yet open
Preoperative Physical Exercise, Nutritional Support, and Psychological Intervention (Multimodal Prehabilitation) to Strengthen Patients' Overall Health and Reduce Postoperative Complications
NCT07389746Cancer Surgery, Prehabilitation
University Hospital of Cologne
Not applicable
400
Cologne
2026-07-01
Not yet open
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
NCT07507968Esophagogastric Adenocarcinoma
DrugDurvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
101
Berlin, Cologne, Essen, Frankfurt am Main, Göttingen, Halle, Hamburg, Heidelberg
2026-07-01
Recruiting
Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.
NCT07647471Pediatric Cancer Patients
Universität Duisburg-Essen
Not applicable
346
Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz
2026-07-01
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
DrugElecoglipron
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsALXN2220·Eplontersen
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Cisplatin·Carboplatin
Boehringer Ingelheim
Phase 2
60
Cologne, Heidelberg
2026-06-04
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
Erlangen, Frankfurt am Main, Marburg, Cologne, Düsseldorf, Homburg, Berlin
2026-06-02
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Tübingen, Giessen, Cologne
2026-06-01
Not yet open
An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function
NCT07613398Congenital Heart Diseases, Cardiac Diseases
Matthias Stuber
Observational
300
Bonn, Cologne, Berlin
2026-06
Not yet open
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124Treatment Resistant Psychosis, Psychosis
University of Oxford
Phase 3
250
Berlin, Cologne, Munich
2026-06
Not yet open
Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study
NCT07376447Acute Ischemic Stroke
iVascular S.L.U.
Not applicable
160
Bremen, Cologne, Dortmund, Hamburg, Nuremberg
2026-05-31
Recruiting
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
NCT07645443Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
Stephanie Mehl
Not applicable
252
Mannheim, Augsburg, München, Hamburg, Marburg, Cologne, Berlin
2026-05-27
Recruiting
A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma
NCT07353099Thrombotic Thrombocytopenic Purpura (TTP)
Takeda
Observational
50
Bonn, Cologne, Jena, Leipzig, München
2026-05-26
Recruiting
BIO|STREAM.CSP Study
NCT07393009Cardiac Pacing, Cardiac Pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices
Biotronik SE & Co. KG
Observational
1,000
Bad Krozingen, Bad Nauheim, Bad Oeynhausen, Cologne, Osnabrück
2026-05-25
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
5,700
Mannheim, Muehldorf Am Inn, Munich, Weiden in Der Oberpfalz, Frankfurt am Main, Hanover, Cologne, Essen
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
5,610
Aachen, Bad Friedrichshall, Bad Oeynhausen, Berlin, Bochum, Coburg, Cologne, Dresden
2026-05-11
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
DrugsFPI-2265·Xofigo·Cabazitaxel·Zytiga
AstraZeneca
Phase 3
670
Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe
2026-05-04
Recruiting
Glycolytic Phenotype (vLapeak) and Magnitude of Skeletal Muscle Hypertrophy After Resistance Training
NCT07721766Healthy Volunteers, Muscle Hypertrophy, Glycolysis, Moderately Trainend
Technical University of Munich
Not applicable
120
München, Cologne, Düsseldorf, Chemnitz, Leipzig
2026-05-04
Not yet open
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
DrugCannabidiol
University of Oxford
Phase 3
586
Berlin, Cologne, Lübeck, München
2026-05-01
Recruiting
Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
NCT07655479Cardiogenic Shock Post Myocardial Infarction
University Hospital of Cologne
Observational
115
Düsseldorf, Kiel, Cologne
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Cologne, Giessen, Greifswald, Hamburg, Hanover, Munich
2026-04-23
Recruiting
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
University of Regensburg
Not applicable
384
Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne
2026-04-21
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Berlin, Cologne, Essen, Frankfurt am Main
2026-04-17
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Berlin, Bochum, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2026-04-09
Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
NCT06792994Chronic Lymphocytic Leukemia
German CLL Study Group
Observational
2,000
Cologne, Ulm
2026-04-02
Recruiting
Improved Management of Patients With Recent-Onset Stable Chest Pain
NCT07476040Coronary Artery Disease (CAD)
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
DrugApecotrep
Boehringer Ingelheim
Phase 2
132
Berlin, Cologne, Hamburg, Hanover, Mainz, München
2026-03-23
Recruiting
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
NCT07366086Osteogenesis Imperfecta
Amgen
Phase 3
71
Cologne, Würzburg
2026-03-18
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
Cologne, Lübeck, Frankfurt, Mainz
2026-03-16
Recruiting
Neonatal Data and Biobank to Study Factors Influencing Development in Preterm Infants Born at <32 Weeks' Gestation and/or <1500 g Birth Weight
NCT07490912Preterm Infant Development, Preterm Infant Health, Prematurity Complications, Premature Birth
University Hospital of Cologne
Observational
1,300
Cologne
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
DrugsPumitamig·Pembrolizumab
Bristol-Myers Squibb
Phase 3
750
Wangen, Landshut, Rosenheim, Kaiserslautern, Langen, Wiesbaden, Cologne, Dortmund
2026-03-12
Recruiting
Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms
NCT07529275Complex Abdominal Aortic Aneurysms
iVascular S.L.U.
Not applicable
165
Cologne, Hamburg, Leipzig, München
2026-02-16
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
DrugApecotrep
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Berlin, Cologne, Frankfurt, Hamburg, München
2026-02-11
Recruiting
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
NCT07392372HIV -1 Infection
BioNTech SE
Phase 1
67
Cologne, Mannheim
2026-02-09
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
DrugsEYP-1901·Aflibercept
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Cologne
2026-02-09
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Cologne, Dresden, Duisburg, Essen, Hamburg, Leipzig, Lingen, Mainz
2026-02-06
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Tübingen, Cologne, Berlin
2026-01-22
Recruiting
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
NCT07025824AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)
DrugsTreosulfan·Melphalan·Fludarabine
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
Berlin, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Heidelberg, Oldenburg
2026-01-16
Recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901Obesity With Diabetes, Overweight With Diabetes
DrugRibupatide
Kailera
Phase 3
1,156
Tübingen, Falkensee, Cologne, Essen, Oldenburg in Holstein, Schwerin
2026-01-12
By invitation
Lead Evaluation for Defibrillation and Reliability Post Approval Study
NCT07005232Tachyarrhythmia
Medtronic
Observational
2,000
Bielefeld, Cologne, Meerbusch
2026-01-07
Recruiting
Blood Flow Restriction Training in Acute Geriatric Rehabilitation
NCT07291765Sarcopenia in Elderly
University Hospital, Bonn
Not applicable
60
Cologne
2026-01-01
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
DrugsTersolisib·Exemestane·Anastrozole·Ribociclib
Eli Lilly and Company
Phase 3
800
Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Düsseldorf, Erlangen
2025-12-22
Active, closed
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
360
Löwenstein, Frankfurt am Main, Giessen, Cologne
2025-12-22
Recruiting
Vit-A-Vision® Clinical Investigation
NCT06596733Burning Eye, Irritation; Eyeball, Tired Eye, Dry Eye Disease
OmniVision GmbH
Not applicable
77
Cologne
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Munich, Leipzig, Bad Homburg, Berlin, Cologne, Dresden, Essen, Hamburg
2025-12-19
Recruiting
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
NCT07284875Obesity, Overweight
DrugRibupatide
Kailera
Phase 3
2,340
Tübingen, Falkensee, Cologne, Essen, Dresden, Leipzig, Oldenburg in Holstein, Hamburg
2025-12-18
Recruiting
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
NCT07314164Neuroendocrine Tumors
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
NCT07280585Polycystic Kidney, Autosomal Dominant
DrugDapagliflozin
University of Cologne
Phase 3
420
Stuttgart, Nuremberg, Aachen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf
2025-12-16
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen
2025-12-12
Recruiting
BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF
NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
300
Bad Oeynhausen, Cologne, Hamburg, München
2025-12-11
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg
2025-12-10
Recruiting
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
NCT07285213Clostridioides Difficile Infection
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945Chronic Kidney Disease
DrugDapagliflozin
Boehringer Ingelheim
Phase 3
120
Cologne, Hamburg, Heidelberg, Tübingen
2025-12-09
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
Bad Bentheim, Cologne, Münster, Bonn, Mainz
2025-12-04
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Aschaffenburg, Bielefeld, Bochum, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg
2025-12-03
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
München, Cologne, Essen, Dresden, Berlin, Mannheim, Tübingen
2025-12-03
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Cologne, Essen, Goch, Hamburg, Oldenburg, Stuhr
2025-12-01
Recruiting
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
NCT07281833Breast Cancer, HR-positive Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
DrugCapivasertib
Women's Cancer Study Group GmbH
Phase 3
250
Cologne, Essen, Mönchengladbach, Münster, Frankfurt, Hamburg, Hildesheim, München
2025-11-27
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Giessen, Cologne, Tübingen
2025-11-19
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Erlangen, Göttingen, Cologne, Berlin
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Incorporated
Phase 2
26
Berlin, Cologne
2025-11-19
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Bonn, Sulzbach, Cologne, Giessen, Mainz, München, Münster, Tübingen
2025-11-10
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsLiso-cel·Procarbazine·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab Deruxtecan·Docetaxel
AstraZeneca
Phase 3
400
Bad Saarow, Bielefeld, Bonn, Cologne, Essen, Frankfurt, Freiburg im Breisgau, Gauting
2025-10-31
Recruiting
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
NCT06934967Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
12
Cologne, Berlin
2025-10-28
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Rows per page Showing 1–100 of 612
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-germany/city/cologne

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 612 of those studies with a site in Cologne.

How many clinical trials are recruiting in Cologne?

312 of the 612 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 27 have not yet opened recruitment, 261 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Cologne), 612 studies
PhaseStudiesRecruitingShare
Phase 324210439.5%
Observational1218219.8%
Phase 2864214.1%
Not applicable703411.4%
Phase 1/241276.7%
Phase 128114.6%
Phase 2/31792.8%
Phase 4621%
Phase EARLY_PHASE1110.2%

Most active sponsors

Lead sponsors with the most studies (Cologne)
Lead sponsorStudiesRecruiting
AstraZeneca4822
Novartis Pharmaceuticals2910
University of Cologne2517
Bristol-Myers Squibb2110
Janssen Research & Development, LLC216
Eli Lilly and Company209
Boehringer Ingelheim1510
AbbVie146
Hoffmann-La Roche145
Amgen123
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.